Advertisement
Advertisement
VVOS
Vivos Therapeutics, Inc. Common Stock
0.32
USDSponsored
-0.01
-1.94%
Aug 10, 15:59 UTC -4
Closed
After-Market
0.31
-0.01
-1.79%
VVOS Earnings Reports
Positive Surprise Ratio
VVOS beat 8 of 21 last estimates.
38%
Next Report
Next Week
Date of Next Report
Aug 17, 2026
Estimate for Q2 26 (Revenue/ EPS)
$5.47M
/-$0.39
Implied change from Q1 26 (Revenue/ EPS)
+6.48%
/-25.00%
Implied change from Q2 25 (Revenue/ EPS)
+43.30%
/-29.09%
Vivos Therapeutics, Inc. Common Stock earnings per share and revenue
On May 20, 2026, VVOS reported earnings of -0.52 USD per share (EPS) for Q1 26, missing the estimate of -0.46 USD, resulting in a -12.46% surprise. Revenue reached 5.14 million, compared to an expected 4.31 million, with a 19.29% difference. The market reacted with a -0.88% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.39 USD, with revenue projected to reach 5.47 million USD, implying an decrease of -25.00% EPS, and increase of 6.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
Nature's Sunshine Products Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.27
Actual
$0.21
Surprise
-23.75%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Vivos Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Vivos Therapeutics, Inc. Common Stock reported EPS of -$0.52, missing estimates by -12.46%, and revenue of $5.14M, 19.29% above expectations.
How did the market react to Vivos Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.88%, changed from $0.59 before the earnings release to $0.58 the day after.
When is Vivos Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 17, 2026.
What are the forecasts for Vivos Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Vivos Therapeutics, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $5.47M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement